Find Paid Clinical Trials in New York, New York

Paid Clinical Trials and Focus Groups by Location

All Locations ... United States » ... New York » ... New York City

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol dose A; Drug: Indacaterol dose B; Drug: Indacaterol dose C; Drug: Indacaterol dose D; Drug: Placebo; Drug: Salmeterol
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Management Practices and the Risk of Infection Following Cardiac Surgery

Conditions: Cardiac Surgery; Infection, Postoperative Wound; Postoperative Wound Infection; Infections, Nosocomial; Management Practices
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010
Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers

Condition: Kidney Stones
Intervention: Drug: Sodium thiosulfate
Sponsor: VA New York Harbor Healthcare System
Recruiting - verified March 2010
Evaluation of PillCam® Express Capsule Endoscopy Delivery System

Conditions: Small Bowel Disease; Inflammatory Bowel Disease
Intervention: Device: PillCam® Express Capsule Endoscopy Delivery System
Sponsor: Given Imaging Ltd.
Recruiting - verified March 2010
Study of the Sensitivity of Manual vs Electric Aspiration to Detect Completed Early Abortion

Condition: Induced Abortion
Intervention: Procedure: D & C abortion
Sponsors: Planned Parenthood of New York City, Inc.; Society of Family Planning
Not yet recruiting - verified March 2010
Prophylactic Phenobarbital After Neonatal Seizures

Condition: Neonatal Seizures
Interventions: Drug: phenobarbital; Drug: placebo
Sponsor: University of Rochester
Not yet recruiting - verified March 2010
A Study for Adolescents With Fibromyalgia Syndrome

Condition: Fibromyalgia
Intervention: Drug: Duloxetine
Sponsor: Eli Lilly and Company
Not yet recruiting - verified March 2010
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab; Other: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified March 2010
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis(ALS)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Placebo; Drug: 250 mg CK-2017357; Drug: 500 mg CK-2017357
Sponsor: Cytokinetics
Recruiting - verified March 2010
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: NN5401; Drug: insulin detemir; Drug: insulin aspart; Drug: insulin aspart
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis

Condition: Primary Sclerosing Cholangitis
Intervention: Drug: ursodeoxycholic acid (UDCA) withdrawal and reinstitution
Sponsors: University of Tennessee; Mount Sinai School of Medicine; Children's Memorial Hospital; University of California, San Francisco; The Hospital for Sick Children; University of Colorado, Denver; Children's Hospital Medical Center, Cincinnati; University of Pittsburgh
Not yet recruiting - verified March 2010
Study to Investigate CAL-101 in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Conditions: Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Drug: CAL-101; Drug: Rituximab; Drug: Bendamustine
Sponsor: Calistoga Pharmaceuticals, Inc.
Not yet recruiting - verified March 2010
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis

Condition: Lupus Nephritis
Interventions: Drug: laquinimod 0.5mg + standard of care; Drug: laquinimod 1mg + standard of care; Other: placebo + standard of care
Sponsor: Teva Pharmaceutical Industries
Not yet recruiting - verified March 2010
The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke

Condition: Stroke
Interventions: Other: Botox®; Other: saline solution
Sponsor: New York Presbyterian Hospital
Recruiting - verified March 2010
Digital Mammography for the Detection and Preoperative Staging of Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)
Sponsors: Memorial Sloan-Kettering Cancer Center; GE Healthcare
Recruiting - verified March 2010
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030 plus Lucentis; Drug: Lucentis
Sponsor: Ophthotech Corporation
Recruiting - verified March 2010
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Not yet recruiting - verified March 2010
Female Cancer Patients' Preference For Sexual Health Interventions

Conditions: Breast Cancer; Gynecologic Cancer
Intervention:
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

Condition: Influenza
Intervention: Biological: Inactivated Influenza A/H5N1/Indonesia/05/05 (clade 2)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified February 2010
Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy

Condition: Diabetic Peripheral Neuropathy
Interventions: Other: Skin biopsy; Other: Skin biopsy
Sponsors: Albany Medical College; Endo Pharmaceuticals
Recruiting - verified March 2010
Intraarterial Cerebral Infusion of Avastin for Vestibular Schwannoma (Acoustic Neuroma)

Condition: Vestibular Schwannoma
Intervention: Drug: Bevacizumab (Avastin)
Sponsor: Weill Medical College of Cornell University
Not yet recruiting - verified March 2010
Prophylactic Continuous Positive Airway Pressure (CPAP) in Delivery Room, in the Prevention of Transient Tachypnea of Newborn (TTN): A Randomized Controlled Trial

Condition: Transient Tachypnea
Intervention: Other: Prophylactic CPAP Administration
Sponsor: New York Hospital Queens
Recruiting - verified February 2010
Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder

Conditions: Depression; Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified March 2010
Peripartum Cardiomyopathy

Condition: Pregnant Women With Peripartum Cardiomyopathy
Intervention:
Sponsors: University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified March 2010
Draining PLN and Synovial Inflammation in RA Knee Joints Pre and Post Anti-TNF or B Cell Depletion Therapy

Condition: Rheumatoid Arthritis
Intervention:
Sponsor: University of Rochester
Recruiting - verified March 2010
Catheter Ablation for Atrial Fibrillation and Heart Failure

Conditions: Congestive Heart Failure; Atrial Fibrillation; Arrhythmia
Intervention: Procedure: Pulmonary Vein Isolation (PVI)
Sponsor: St. Luke's-Roosevelt Hospital Center
Not yet recruiting - verified March 2010
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Conditions: Advanced Gastric Cancer; Gastro-esophageal Junction Cancer
Interventions: Drug: AUY922; Drug: Docetaxel or Irinotecan
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified March 2010
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: NN1250; Drug: insulin glargine; Drug: NN1250; Drug: insulin aspart
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicines.

Condition: Acute Gout
Interventions: Drug: ACZ885; Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure

Condition: Heart Failure
Intervention: Biological: ACRX-100
Sponsor: Juventas Therapeutics, Inc.
Recruiting - verified March 2010
A Study in Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsor: Eli Lilly and Company
Not yet recruiting - verified March 2010
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Condition: Melanoma
Intervention: Biological: NY-ESO-1 protein; Poly-ICLC; Montanide
Sponsors: Bhardwaj, Nina, M.D.; Ludwig Institute for Cancer Research; Oncovir, Inc.
Not yet recruiting - verified March 2010
Continuous Glucose Monitoring in Type 2 Diabetes Mellitus

Condition: Diabetic Vascular Complications
Intervention:
Sponsor: Winthrop University Hospital
Recruiting - verified March 2010
Vitamin D Levels in Stage IV Colorectal Cancer Patients

Condition: Colorectal Cancer
Intervention: Dietary Supplement: vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Polyneuropathy
Interventions: Drug: SB-509; Other: Saline
Sponsors: Sangamo Biosciences; Juvenile Diabetes Research Foundation
Recruiting - verified March 2010
The Saint Francis Remote Ischemic Preconditioning Trial (SaFR)

Condition: Coronary Artery Disease
Interventions: Other: Remote ischemic preconditioning; Other: Sham Remote Ischemic Preconditioning
Sponsor: St. Francis Hospital, New York
Not yet recruiting - verified February 2010
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: olaparib; Drug: paclitaxel; Drug: carboplatin
Sponsor: AstraZeneca
Recruiting - verified March 2010
Randomized Trial Comparing Robotic and Open Radical Cystectomy

Condition: Bladder Cancer
Interventions: Procedure: open radical cystectomy; Procedure: robotic-assisted radical cystectomy
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)

Condition: Advanced Renal Cell Carcinoma
Interventions: Drug: Tivozanib; Drug: Sorafenib
Sponsor: AVEO Pharmaceuticals, Inc.
Not yet recruiting - verified February 2010
Febuxostat Versus Allopurinol or Placebo in Subjects With Hyperuricosuria and Calcium Oxalate Stones

Conditions: Hyperuricosuria; Kidney Stones
Interventions: Drug: Febuxostat; Drug: Allopurinol; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified February 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

Condition: Fibromyalgia
Interventions: Drug: Placebo; Drug: Milnacipran
Sponsors: Forest Laboratories; Cypress Bioscience, Inc.
Recruiting - verified February 2010
Training Executive, Attention and Motor Skills (TEAMS): Preliminary Studies

Condition: Attention Deficit Hyperactivity Disorder
Intervention: Other: TEAMS (Training Attention Executive and Motor Skills)
Sponsor: Queens College, The City University of New York
Recruiting - verified February 2010
Comparison of Critical Flicker Fusion Versus Automated Visual Fields in the Detection of Early Glaucoma

Condition: Glaucoma
Intervention:
Sponsors: North Shore Long Island Jewish Health System; Nassau University Medical Center
Recruiting - verified February 2010
Autoimmunity in Sisters of Lupus Patients

Condition: Systemic Lupus Erythematosus
Intervention:
Sponsors: North Shore Long Island Jewish Health System; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
A Study in Depression and Associated Painful Physical Symptoms

Condition: Major Depressive Disorder
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Not yet recruiting - verified March 2010
Treatment Interruption of Natalizumab

Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: interferon beta 1-a; Drug: methylprednisolone; Other: IV placebo; Drug: glatiramer acetate
Sponsors: Biogen Idec; Elan Pharmaceuticals
Not yet recruiting - verified February 2010
12-week Efficacy of Indacaterol

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol; Drug: Placebo
Sponsor: Novartis
Recruiting - verified February 2010
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Interventions: Drug: A: Azacitidine (Vidaza); Drug: B: Conventional Care Regimen
Sponsor: Celgene Corporation
Not yet recruiting - verified February 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Condition: Chronic Plaque-type Psoriasis
Interventions: Drug: AIN457; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified February 2010
Asthma Education Using Child Life Services and an Asthma-based Computer Game

Condition: Asthma
Intervention: Other: Quest for the Code
Sponsors: Winthrop University Hospital; Asthma Coalition of Long Island
Recruiting - verified February 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

Conditions: Hyperphosphatemia; End-Stage Renal Disease
Intervention: Drug: ferric citrate
Sponsor: Keryx Biopharmaceuticals
Not yet recruiting - verified February 2010
Athena Pelvic Muscle Trainer - DUETS Trial

Condition: Urinary Incontinence
Intervention: Device: Athena Pelvic Muscle Trainer
Sponsor: Athena Feminine Technologies, Inc.
Recruiting - verified March 2010
Trial of Comprehensive Migraine Intervention

Condition: Migraine
Interventions: Drug: Naproxen; Drug: Sumatriptan; Behavioral: Migraine education; Behavioral: Reenforcement of diagnosis; Other: Typical care
Sponsor: Montefiore Medical Center
Recruiting - verified February 2010
Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

Condition: Influenza
Intervention: Drug: Peramivir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified January 2010
Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing

Condition: Heart Failure
Intervention: Drug: LMI 1195
Sponsor: Lantheus Medical Imaging
Not yet recruiting - verified March 2010
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Condition: Sarcoma
Intervention: Drug: temsirolimus
Sponsors: Albert Einstein College of Medicine of Yeshiva University; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study in Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide; Drug: LY2189265; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Eltrombopag; Drug: Eltrombopag
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

Condition: Influenza
Interventions: Drug: Favipiravir; Drug: Favipiravir; Drug: Placebo comparator
Sponsor: Toyama Chemical Co., Ltd.
Recruiting - verified March 2010
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis

Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Not yet recruiting - verified February 2010
Early Prediction of Pathologic Complete Response (pathCR) With Fluoro-L-Thymidine (FLT) Positron Emission Tomography (PET)

Condition: Esophageal Cancer
Intervention: Drug: Fluoro-L-Thymidine
Sponsors: Columbia University; National Cancer Institute (NCI)
Recruiting - verified February 2010
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Condition: Myelodysplastic Syndrome
Interventions: Drug: Ezatiostat Hydrochloride; Drug: Lenalidomide (Revlimid®)
Sponsor: Telik
Recruiting - verified February 2010
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

Condition: Glaucoma
Interventions: Drug: AR-12286 0.5% ophthalmic solution; Drug: AR-12286 0.25% Ophthalmic solution; Drug: Latanoprost ophthalmic solution
Sponsor: Aerie Pharmaceuticals
Recruiting - verified March 2010
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: Oxycodone controlled release (CR); Drug: Tapentadol extended release (ER)
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified February 2010
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: Ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Dalteparin in Combination With Sunitinib in Patients With Metastatic Kidney Cancer

Condition: Renal Cell Carcinoma
Intervention: Drug: Sunitinib and Dalteparin mono and combination therapy
Sponsors: Roswell Park Cancer Institute; Pfizer
Recruiting - verified March 2010
Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®

Condition: Osteoarthritis
Interventions: Drug: LT-NS001; Drug: Naprosyn®
Sponsors: Logical Therapeutics; PRA International
Recruiting - verified February 2010
Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

Conditions: Inflammation; Pain
Interventions: Drug: Loteprednol etabonate; Drug: Vehicle of Loteprednol Etabonate
Sponsor: Bausch & Lomb, Inc.
Recruiting - verified February 2010
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified January 2010
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: OPC-34712 + ADT; Drug: Placebo + ADT
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2010
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Condition: Infantile Hemangioma
Interventions: Drug: Propranolol; Drug: Placebo
Sponsor: Pierre Fabre Dermatology
Recruiting - verified March 2010
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer

Conditions: Pancreatic Cancer; Colorectal Cancer
Intervention: Biological: Cancer macrobead placement in abdominal cavity
Sponsor: The Rogosin Institute
Recruiting - verified March 2010
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Condition: Multiple Myeloma
Interventions: Drug: lenalidomide; Drug: melphalan
Sponsors: Weill Medical College of Cornell University; Celgene Corporation
Recruiting - verified March 2010
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified March 2010
Ixabepilone + Carboplatin Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Carboplatin
Sponsor: US Oncology Research
Recruiting - verified February 2010
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Condition: Schizophrenia
Interventions: Drug: LY2140023; Drug: Placebo; Drug: Standard of Care
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

Condition: Hypertriglyceridemia
Interventions: Drug: AMR101 (ethyl icosapentate); Drug: AMR101 (ethyl icosapentate); Drug: Placebo
Sponsor: Amarin Pharma Inc.
Recruiting - verified February 2010
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

Condition: Pediatric Solid Tumors
Intervention: Drug: perifosine + temsirolimus
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Wisconsin, Madison; NATL COMP CA NETWORK; Wyeth; AOI Pharmaceuticals, Inc.
Recruiting - verified March 2010
To Assess the Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide at Two Dose Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe, Stable COPD

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide; Drug: aclidinium bromide
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Preventative Misconception Intervention

Conditions: HIV; HIV Infections
Interventions: Behavioral: 1-sided messages; Behavioral: 2-sided messages
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified February 2010
To Assess the Long-term Safety, Efficacy and Tolerability of Inhaled Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

Conditions: Schizophrenia; Bipolar Disorder; Autistic Disorder; Attention Deficit and Disruptive Behavior Disorders
Interventions: Drug: Other atypical antipsychotic drugs; Drug: Risperidone
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: sitagliptin
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide/formoterol fumarate combination; Drug: aclidinium bromide/formoterol fumarate combination; Drug: aclidinium bromide; Drug: formoterol fumarate; Drug: placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy

Condition: Partial Epilepsy
Intervention: Drug: VX-765
Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting - verified February 2010
Open Label Pilot Study of Apremilast in Treatment of Rosacea

Conditions: Erythematotelangiectatic Rosacea; Papulopustular Rosacea
Intervention: Drug: Apremilast
Sponsors: Columbia University; Celgene Corporation
Not yet recruiting - verified February 2010
Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN5401; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified February 2010
A Study is to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered Tapentadol ER at Dosages of 100 to 250 mg Twice Daily Compared With Placebo in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: tapentadol extended release (ER); Drug: placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified February 2010
12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress

Conditions: Sexual Dysfunctions, Psychological; Depression
Interventions: Drug: flibanserin 2; Drug: placebo; Drug: flibanserin 1
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.

Conditions: Liver Neoplasms; Adenoma; Carcinoma; Liver Abscess
Intervention: Drug: Gadoxetic Acid Disodium (Primovist/Eovist, BAY86-4873)
Sponsor: Bayer
Recruiting - verified March 2010
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Disease-modifying antirheumatic drug
Sponsor: Pfizer
Recruiting - verified March 2010
A Study in Semagacestat for Alzheimer's Patients

Condition: Alzheimer's Disease
Intervention: Drug: Semagacestat
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

Condition: Familial Amyotrophic Lateral Sclerosis
Intervention: Drug: Pyrimethamine
Sponsors: Weill Medical College of Cornell University; Muscular Dystrophy Association
Recruiting - verified March 2010
Genotype-Phenotype Correlations of LINCL (2)

Conditions: Batten Disease; Late Infantile Neuronal Lipofuscinosis
Intervention:
Sponsor: Weill Medical College of Cornell University
Not yet recruiting - verified March 2010
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: AS1411; Drug: Cytarabine
Sponsor: Antisoma Research
Recruiting - verified March 2010
Efficacy and Safety of EN3324 in Subjects With Chronic Low Back Pain

Condition: Chronic Low Back Pain
Interventions: Drug: EN3324; Drug: Placebo
Sponsor: Endo Pharmaceuticals
Recruiting - verified March 2010
Interleukin 2, Aldesleukin and Entinostat for Kidney Cancer

Condition: Renal Cell Carcinoma
Intervention: Drug: Aldesleukin
Sponsor: Roswell Park Cancer Institute
Recruiting - verified March 2010
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

Condition: Diabetes
Interventions: Drug: MBX-2982; Drug: MBX-2982; Drug: MBX-2982; Drug: Sitagliptin; Drug: placebo
Sponsor: Metabolex
Recruiting - verified March 2010
Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer

Condition: Esophageal Neoplasm
Intervention: Drug: HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)
Sponsor: Roswell Park Cancer Institute
Recruiting - verified March 2010
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults

Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2009
CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified February 2010
Efficacy and Safety of TAK-491 and Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension.

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Comparison of Depression Interventions After Acute Coronary Syndrome

Conditions: Acute Coronary Syndrome; Depression
Interventions: Behavioral: Problem Solving Therapy; Drug: Sertraline, citalopram, or bupropion; Other: Standard care
Sponsors: Columbia University; National Heart, Lung, and Blood Institute (NHLBI); The University of North Carolina, Chapel Hill; Emory University; Yale University; Washington University School of Medicine; University of Pennsylvania
Recruiting - verified March 2010
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma

Condition: Advanced Renal Cell Carcinoma
Interventions: Drug: tivozanib (AV-951); Drug: Sorafenib
Sponsor: AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2010
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: carfilzomib, lenalidomide plus dexamethasone; Drug: carfilzomib, lenalidomide plus dexamethasone
Sponsors: University of Michigan Cancer Center; Onyx Therapeutics, Inc.; Celgene Corporation
Recruiting - verified February 2010
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified March 2010
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Condition: Hepatitis C Virus
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: Peginterferon Alfa-2a; Drug: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 formulation 3; Drug: GSK2248761 formulation 1; Drug: GSK2248761 reference formulation; Drug: GSK2248761 formulation 2 or 4
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: prednisone; Drug: vincristine sulfate; Drug: vinorelbine ditartrate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Preservative-Free Tafluprost (MK2452) for Open-Angle Glaucoma/Ocular Hypertension

Conditions: Open-Angle Glaucoma; Ocular Hypertension
Interventions: Drug: Preservative-Free MK2452 (Tafluprost); Drug: Comparator: timolol
Sponsor: Merck
Recruiting - verified March 2010
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2010
A Long Term Safety Study of MK4305 in Patients With Primary Insomnia

Condition: Insomnia
Interventions: Drug: MK4305; Drug: Comparator: Placebo to MK4305
Sponsor: Merck
Recruiting - verified March 2010
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: rifampin; Drug: midazolam; Drug: ketoconazole; Drug: brentuximab vedotin
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Condition: Malignant Melanoma
Interventions: Drug: BMS-936558 (MDX1106-04); Drug: Ipilimumab
Sponsors: Bristol-Myers Squibb; Medarex; Ono Pharma
Recruiting - verified February 2010
Polysomnography Study of MK6096 in Patients With Primary Insomnia

Condition: Primary Insomnia
Interventions: Drug: MK6096 2.5 mg and placebo; Drug: Comparator: MK6096 5 mg and placebo; Drug: Comparator: MK6096 10 mg and placebo; Drug: Comparator: MK6096 20 mg and placebo
Sponsor: Merck
Recruiting - verified March 2010
Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1)

Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (SCH 503034); Drug: erythropoietin; Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID)for Knee Pain Due to Osteoarthritis

Condition: Osteoarthritis Knee Pain
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Condition: HIV Infections
Interventions: Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR); Drug: 3-4 commercially available antiretroviral drugs
Sponsor: Myriad Pharmaceuticals
Recruiting - verified March 2010
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

Condition: Hodgkin Lymphoma
Intervention: Drug: Everolimus (RAD001)
Sponsor: Novartis
Recruiting - verified March 2010
Clinical Evaluation of the PROGENSA(R) PCA3 Assay in Men With a Previous Negative Biopsy Result

Condition: Prostatic Neoplasms
Intervention: Other: PCA3 Assay
Sponsor: Gen-Probe, Incorporated
Recruiting - verified March 2010
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection

Condition: Cervical Intraepithelial Neoplasia
Interventions: Drug: RO5217790; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Effects of Intensified Sodium Management in Hemodialysis Patients

Condition: Hemodialysis
Intervention: Other: intensive sodium management
Sponsor: Renal Research Institute
Recruiting - verified March 2010
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma

Condition: Asthma
Interventions: Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Condition: Leukemia
Intervention: Drug: AEG35156
Sponsor: Aegera Therapeutics
Recruiting - verified February 2010
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

Condition: Acne Vulgaris
Interventions: Drug: Tazarotene foam; Drug: Vehicle Foam
Sponsor: Stiefel, a GSK Company
Recruiting - verified February 2010
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By Chemotherapy With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsor: Pharmacyclics
Recruiting - verified February 2010
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Diabetes Support Project: Couples Intervention

Condition: Type 2 Diabetes
Interventions: Behavioral: Telephone support and behavior change; Other: Diabetes self-management education
Sponsor: State University of New York - Upstate Medical University
Recruiting - verified February 2010
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GW642444 Inhalation Powder; Drug: FF/GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Condition: Onychomycosis
Interventions: Drug: IDP-108; Drug: Vehicle
Sponsor: Dow Pharmaceutical Sciences
Recruiting - verified March 2010
BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

Condition: Schizophrenia
Interventions: Drug: GSK239512; Drug: Placebo; Drug: d-amphetamine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
AZD6244 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: MEK inhibitor AZD6244; Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

Condition: Leukemia
Intervention: Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: Southern blotting; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study Evaluating the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis

Condition: Active Rheumatoid Arthritis
Intervention: Drug: SBI-087
Sponsor: Wyeth
Recruiting - verified February 2010
ACT-128800 in Relapsing-remitting Multiple Sclerosis

Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: ACT-128800; Drug: Placebo
Sponsor: Actelion
Recruiting - verified February 2010
Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain

Condition: Back Pain
Interventions: Drug: REGN475/SAR164877; Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified March 2010
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

Condition: Diffuse Large B Cell Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: vincristine; Drug: doxorubicin; Drug: prednisone; Drug: azacytidine
Sponsors: Weill Medical College of Cornell University; Celgene Corporation
Recruiting - verified March 2010
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

Condition: Cystitis, Interstitial
Interventions: Biological: Tanezumab; Biological: Tanezumab; Biological: Tanezumab; Biological: Tanezumab; Other: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Conditions: Acute Coronary Syndrome; Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease
Interventions: Drug: Darapladib 160 mg; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Guided Biopsy for Mapping Prostate Cancer

Condition: Prostate Cancer
Intervention: Procedure: Prostatectomy
Sponsor: Roswell Park Cancer Institute
Not yet recruiting - verified March 2010
Study to Assess VB-201 in Patients With Psoriasis

Condition: Active Plaque Psoriasis
Interventions: Drug: VB-201; Drug: VB-201; Other: Placebo
Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics
Recruiting - verified March 2010
Lenalidomide as a Chemopreventive Agent for High-Risk Early Stage B-cell Chronic Lymphocytic Leukemia (CLL)

Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Lenalidomide
Sponsors: Roswell Park Cancer Institute; Celgene Corporation
Recruiting - verified March 2010
Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan

Condition: Colorectal Cancer
Intervention: Drug: cetuximab with irinotecan
Sponsor: Roswell Park Cancer Institute
Recruiting - verified February 2010
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)

Condition: Sickle Cell Disease
Interventions: Other: High Demand / Low Infusion; Other: PCA Dosing Plan
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Conditions: Graft-Versus-Host Disease; Immune System Disorders
Interventions: Drug: Mycophenolate Mofetil; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Newtwork (BMT CTN)
Recruiting - verified March 2010
TAXUS Libertē Post Approval Study

Condition: Coronary Artery Disease
Interventions: Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent; Drug: prasugrel; Drug: placebo; Drug: aspirin
Sponsors: Boston Scientific Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified March 2010
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Keryx / AOI Pharmaceuticals, Inc.; Dana-Farber Cancer Institute
Recruiting - verified March 2010
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Conditions: Haemophilus Influenzae Type B Related Disease; Pneumonia; Meningitis; Cellulitis; Osteomyelitis; Epiglottis
Interventions: Biological: InfanrixTM; Biological: GSK Biologicals' Haemophilus inluenzae type b vaccine (GSK 208108); Biological: ActHIBTM; Biological: PentacelTM; Biological: PediarixTM; Biological: PrevnarTM; Biological: RotarixTM; Biological: EngerixTM-B
Sponsor: GlaxoSmithKline
Not yet recruiting - verified March 2010
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Condition: Triple Negative Breast Cancer
Intervention: Drug: Temsirolimus, cisplatin, erlotinib
Sponsors: Columbia University; Wyeth; Genentech
Recruiting - verified March 2010
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Linagliptin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly

Condition: Acromegaly
Intervention: Drug: BIM 23A760
Sponsor: Ipsen
Recruiting - verified March 2010
Safety and Tolerability of TAK-491 Plus Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Essential Hypertension

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip
Interventions: Other: Tanezumab 2.5 mg; Other: Tanezumab 5 mg; Other: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified March 2010
Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection

Conditions: HIV Infections; Hepatitis C Virus
Interventions: Drug: Nitazoxanide (NTZ); Drug: Peginterferon alfa-2a (PEG-INF); Drug: Ribavirin (RBV)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
The Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis to Assess the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo; Biological: Certolizumab pegol
Sponsor: UCB, Inc.
Recruiting - verified March 2010
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis

Condition: Psoriasis
Interventions: Drug: Etanercept ONLY; Drug: Methotrexate and Etanercept
Sponsors: Amgen; Immunex Corporation
Recruiting - verified March 2010
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: flibanserin; Drug: placebo; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
IMGN901 in Combination With Lenalidomide and Dexamethasone

Condition: Multiple Myeloma
Intervention: Drug: IMGN901
Sponsor: ImmunoGen, Inc.
Recruiting - verified March 2010
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Conditions: Pain; Diabetic Neuropathy, Painful
Interventions: Drug: Placebo; Drug: JNJ-42160443
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Condition: Coronary Artery Disease
Interventions: Drug: Apadenoson; Drug: Adenosine
Sponsors: PGxHealth, LLC; PPD
Recruiting - verified March 2010
Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Dexamethasone USP Micronized; Drug: Prednisone
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Family Cardiac Caregiver Investigation to Evaluate Outcomes

Conditions: Cardiovascular Diseases; Heart Diseases
Intervention:
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2009
Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

Condition: Restless Legs Syndrome
Interventions: Drug: pregabalin; Drug: placebo; Drug: pramipexole
Sponsor: Pfizer
Recruiting - verified March 2010
The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia

Condition: Dyslipidemia
Interventions: Drug: anacetrapib; Drug: Comparator: atorvastatin; Drug: Comparator: placebo to MK0859; Drug: Comparator: placebo to atorvastatin
Sponsor: Merck
Recruiting - verified March 2010
Telephone Support to Improve Adherence to Anti-HIV Medications

Condition: HIV Infections
Interventions: Behavioral: Enhanced nursing telephone support; Behavioral: Standard care
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

Condition: Cancer
Intervention: Drug: TL32711
Sponsor: TetraLogic Pharmaceuticals
Recruiting - verified February 2010
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Intervention: Drug: Compound AC220
Sponsor: Ambit Biosciences Corporation
Recruiting - verified March 2010
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain

Conditions: Pain; Back Pain; Low Back Pain; Back Pain With Radiation
Interventions: Drug: Oxycodone IR; Drug: NUCYNTA
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal
Recruiting - verified February 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Condition: Neoplasms
Interventions: Drug: RG1507; Drug: RAD001
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis

Condition: Amyotrophic Lateral Sclerosis
Interventions: Dietary Supplement: Oxepa; Dietary Supplement: Jevity 1.5; Dietary Supplement: Jevity 1.0
Sponsors: Massachusetts General Hospital; Muscular Dystrophy Association
Recruiting - verified March 2010
Geriatric Group Psychoeducational Intervention for Elderly Patients With Cancer

Conditions: Breast Cancer; Prostate Cancer
Interventions: Behavioral: group intervention and questionnaires; Behavioral: individual phone intervention and questionnaires
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2009
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
Combination Chemotherapy With or Without GDC-0449 in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Gastric Cancer
Interventions: Drug: FOLFOX regimen; Drug: Hedgehog antagonist GDC-0449; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: New York Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Oxycodone User Registry (OUR)

Condition: Pain
Intervention: Drug: oxycodone immediate release (OXYRX)
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
The Dual Antiplatelet Therapy Study (DAPT Study)

Condition: Coronary Artery Disease
Interventions: Drug: Placebo & Aspirin; Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Sponsors: Harvard Clinical Research Institute; Abbott; Boston Scientific Corporation; Bristol-Myers Squibb; Sanofi-Synthelabo; Cordis Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.; Medtronic
Recruiting - verified March 2010
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)

Condition: Typical Atrial Flutter
Intervention: Device: Therapy Cool Path Duo
Sponsor: St. Jude Medical
Recruiting - verified March 2010
A Study of Sorafenib and Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Sorafenib and Everolimus
Sponsors: Roswell Park Cancer Institute; Novartis; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified March 2010
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

Condition: Gastroesophageal Reflux Disease
Interventions: Drug: arbaclofen placarbil; Drug: Placebo
Sponsor: XenoPort, Inc.
Recruiting - verified March 2010
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PF-03463275; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

Condition: Parkinson's Disease
Interventions: Drug: IPX066; Drug: regular carbidopa-levodopa
Sponsor: IMPAX Laboratories, Inc.
Recruiting - verified March 2010
Clinical Study to Test a New Drug to Treat Major Depression

Condition: Major Depressive Disorder (MDD)
Interventions: Drug: GW856653; Other: Placebo; Drug: GW856653
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin glargine + preprandial lispro insulin; Biological: albiglutide + insulin glargine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
TMC435-TiDP16-C206: A Safety and Efficacy Study in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Condition: Hepatitis C
Interventions: Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 placebo /Peg IFNa2A/Ribavirin
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
To Evaluate the Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

Condition: Gastroesophageal Reflux
Interventions: Drug: Rabeprazole sodium capsules; Drug: placebo; Drug: Rabeprazole sodium capsules
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified February 2010
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Condition: Bladder Cancer
Interventions: Drug: Mitomycin C (MMC); Biological: TheracysR Bacillus Calmette-Guerin (BCG)
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone

Condition: Diabetes Mellitus, Type II
Interventions: Drug: Placebo; Drug: Dutogliptin
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

Condition: Bacterial Conjunctivitis
Interventions: Drug: Besifloxacin; Drug: Vehicle (Placebo)
Sponsor: Bausch & Lomb, Inc.
Recruiting - verified February 2010
Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer

Condition: Parents Who Have Lost a Child to Cancer
Intervention: Behavioral: Questionnaires/Interviews
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); Dana Farber Cancer Institute/Harvard Medical School; Ohio State University; University of Memphis
Recruiting - verified March 2010
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Conditions: Pain; Neuralgia, Postherpetic; Neuralgia; Mononeuropathies
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Conditions: Adenocarcinoma; Advanced Breast Cancer; Advanced Metastatic Breast Cancer; ErbB2+; Her2+; Invasive Breast Cancer; Metastatic ErbB2
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: placebo; Drug: rontalizumab
Sponsor: Genentech
Recruiting - verified February 2010
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Conditions: Kidney Cancer; Head and Neck Cancer; Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Esophageal Cancer; Gliomas
Intervention: Drug: 177Lu-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant (MK0524A)) in Patients With Dyslipidemia

Condition: Dyslipidemia
Interventions: Drug: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: Extended-release niacin (ERN); Drug: Comparator: Placebo to ERN/LRPT
Sponsor: Merck
Recruiting - verified March 2010
A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Condition: Hepatitis C, Chronic
Interventions: Drug: RO5190591; Drug: RO5190591; Drug: RO5190591; Drug: RO5190591; Drug: Placebo; Drug: Placebo; Drug: Pegasys; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Conditions: Seasonal Influenza; Cough; Sore Throat; Nasal Congestion; Myalgia; Headache; Fatigue
Interventions: Drug: Peramivir; Drug: Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified March 2010
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: warfarin; Drug: placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Duke University
Recruiting - verified February 2010
Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

Condition: Parkinson's Disease
Interventions: Drug: nicotine; Other: placebo comparator
Sponsor: Neuraltus Pharmaceuticals, Inc.
Recruiting - verified March 2010
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine Carcinosarcoma

Condition: Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

Condition: Gaucher Disease, Type 1
Intervention: Drug: velaglucerase alfa
Sponsor: Shire Human Genetic Therapies, Inc.
Available - verified March 2010
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: TOK-001; Drug: TOK-001; Drug: TOK-001
Sponsor: Tokai Pharmaceuticals
Recruiting - verified February 2010
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

Condition: Subjective Tinnitus
Interventions: Drug: Neramexane mesylate; Drug: Placebo
Sponsor: Merz Pharmaceuticals GmbH
Recruiting - verified March 2010
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

Conditions: Cough; Sore Throat; Nasal Congestion; Headache; Fever; Seasonal Influenza
Interventions: Drug: Peramivir 600mg Adults, Peramivir 10mg/kg Adolescents; Drug: Placebo Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified March 2010
Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen® (Interferon Alfacon 1) in Patients Chronically Infected With Hepatitis C Virus

Condition: Hepatitis C
Intervention: Drug: Infergen with or without ribavirin
Sponsor: Three Rivers Pharmaceuticals
Recruiting - verified March 2010
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Condition: Partial Epilepsies
Intervention: Drug: Lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

Condition: Acute Myeloid Leukemia
Interventions: Drug: AZD1152; Drug: LDAC; Drug: AZD1152 + LDAC
Sponsor: AstraZeneca
Recruiting - verified March 2010
Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

Conditions: Penile Cancer; Erectile Dysfunction; Radical Prostatectomy
Interventions: Drug: Placebo QHS and sildenafil and questionnaires; Drug: Sildenafil and questionnaire; Drug: Trimix combination (Papavarine 30mg/Phentholamine 1mg/Prostaglandin E1 10 mcgs/ml) and questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Pfizer
Recruiting - verified March 2010
Pioglitazone for Oral Premalignant Lesions

Conditions: Mouth Cancer; Oral Cancer
Interventions: Drug: Pioglitazone; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

Condition: Sarcoidosis
Interventions: Drug: Placebo; Drug: golimumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Examining Benefits of HAART Continuation in Postpartum Mothers

Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Preventing Acute Chest Syndrome by Transfusion Feasibility Study

Conditions: Sickle Cell Disease; Secretory Phospholipase A2; sPLA2
Interventions: Biological: Single blood transfusion; Behavioral: Standard care
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
A Study of Trastuzumab-MCC-DM1, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: paclitaxel; Drug: pertuzumab; Drug: trastuzumab-MCC-DM1
Sponsor: Genentech
Recruiting - verified February 2010
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3)

Conditions: HIV Infections; Hepatitis C; HCV Infection
Interventions: Drug: PEG2b plus ribavirin followed by placebo; Drug: PEG2b plus ribavirin followed by boceprevir/PEG2b/ribavirin
Sponsor: Schering-Plough
Recruiting - verified March 2010
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Condition: Haemophilia A or B With Inhibitors
Interventions: Drug: activated recombinant human factor VII, long acting; Drug: activated recombinant human factor VII, long acting; Drug: activated recombinant human factor VII, long acting
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Study of Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin

Condition: Diabetes Mellitus, Type II
Interventions: Drug: Dutogliptin; Drug: Placebo
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
BIBW 2992 Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Interventions: Drug: BIBW 2992; Drug: BIBW 2992; Drug: Cisplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage III or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study

Condition: Ovarian Cancer
Intervention: Procedure: DCE-MRI scans
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Prospective, Multi-Center Clinical Outcomes Study Evaluating the chronOS Strip Combined With Bone Marrow Aspirate

Condition: Degenerative Disc Disease With or Without Stenosis
Intervention: Device: chronOS strip
Sponsor: Synthes Spine
Recruiting - verified March 2010
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

Condition: Asthma
Interventions: Drug: QMF149 Twisthaler®; Drug: Mometasone Twisthaler®
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

Condition: Alzheimer's Disease
Intervention: Drug: Dimebon
Sponsors: Pfizer; Medivation, Inc.
Recruiting - verified March 2010
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2010
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies

Condition: Chronic Hepatitis C Infection (HCV)
Interventions: Drug: vaniprevir (MK7009); Drug: Comparator: Pegylated Interferon (Peg-IFN); Drug: Comparator: Ribavirin (RBV)
Sponsor: Merck
Recruiting - verified March 2010
A Study of V503 in Preadolescents and Adolescents

Conditions: Cervical Cancer; Vulvar Cancer; Vaginal Cancer; Genital Lesions; PAP Test Abnormalities; HPV Infections
Intervention: Biological: V503
Sponsor: Merck
Recruiting - verified March 2010
Clazosentan in Aneurysmal Subarachnoid Hemorrhage

Condition: Aneurysmal Subarachnoid Hemorrhage
Interventions: Drug: Clazosentan; Drug: Clazosentan; Drug: Placebo
Sponsor: Actelion
Recruiting - verified March 2010
Clinical Experience With the Hindfoot Arthrodesis Nail for the Surgical Treatment of Ankle and Hindfoot Pathologies

Conditions: Hindfoot Arthrodesis; Hindfoot Pathologies
Intervention:
Sponsors: AO Clinical Investigation and Documentation; Synthes Inc.
Recruiting - verified March 2010
Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control Cytomegalovirus (CMV) Infection in R+ Hematopoietic Stem Cell Transplant Recipients

Condition: Cytomegalovirus Infection
Interventions: Drug: CMX001; Drug: Placebo
Sponsor: Chimerix
Recruiting - verified March 2010
Study of PKI-587 Administered Intravenously to Subjects With Solid Tumors

Condition: Tumors
Intervention: Drug: PKI-587
Sponsor: Wyeth
Recruiting - verified March 2010
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera

Condition: Polycythemia Vera
Interventions: Drug: Clopidogrel (Plavix); Drug: Placebo; Drug: Aspirin
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Condition: Head & Neck Cancer
Intervention: Drug: RAD001 + docetaxel + cisplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified March 2010
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

Condition: Postmenopausal Osteoporosis
Interventions: Drug: Ibandronate; Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck

Condition: Oral Mucositis
Interventions: Biological: AG013; Biological: AG013; Biological: AG013; Other: Placebo; Other: Placebo; Other: Placebo
Sponsor: ActoGeniX N.V.
Recruiting - verified February 2010
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified March 2010
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsor: Pfizer
Recruiting - verified March 2010
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

Condition: Metastatic Colorectal Cancer
Intervention: Drug: EZN-2208, Cetuximab and Irinotecan
Sponsor: Enzon Pharmaceuticals, Inc.
Recruiting - verified March 2010
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham
Sponsors: Regeneron Pharmaceuticals; Bayer
Recruiting - verified February 2010
28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

Condition: Schizophrenia
Interventions: Drug: oral risperidone; Drug: paliperidone palmitate
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Abatacept Versus Adalimumab Head-to-Head

Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Adalimumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Safety and Efficacy Evaluation of Fx-1006A in Patients With V122I or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

Condition: Amyloid Cardiomyopathy
Intervention: Drug: Fx-1006A
Sponsor: FoldRx Pharmaceuticals
Recruiting - verified February 2010
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Condition: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Drug: Vc-RCHOP; Drug: RCHOP
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: PF-04447943; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects

Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis

Conditions: Primary Myelofibrosis; Post-Polycythemia Vera; Post-Essential Thrombocytopenia
Interventions: Drug: Panobinostat; Drug: Panobinostat
Sponsor: Novartis
Recruiting - verified March 2010
Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Condition: Diabetes Mellitus, Type 2
Intervention: Drug: linagliptin QD for 7 days
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke

Condition: Stroke
Interventions: Drug: Magnesium Chloride; Drug: Placebo
Sponsor: Relox Medical, LLC
Recruiting - verified February 2010
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

Condition: Bronchiectasis
Interventions: Drug: Cipro (Ciprofloxacin, BAYQ3939); Drug: Placebo
Sponsors: Bayer; Novartis
Recruiting - verified February 2010
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Not Responded to Treatment

Conditions: Brain and Central Nervous System Tumors; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

Condition: Scleroderma
Interventions: Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546
Sponsor: MedImmune LLC
Recruiting - verified March 2010
Long Term Safety Study of Tanezumab in Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg; Biological: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified March 2010
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

Condition: Cancer
Intervention: Drug: PF-04691502
Sponsor: Pfizer
Recruiting - verified February 2010
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride; Drug: Placebo
Sponsor: Amicus Therapeutics
Recruiting - verified March 2010
XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)

Condition: Degenerative Disc Disease
Interventions: Device: XL TDR; Other: Lumbar fusion surgery
Sponsor: NuVasive
Recruiting - verified February 2010
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Condition: Schizophrenia and Predominant Negative Symptoms
Interventions: Drug: SPD489 (lisdexamfetamine dimesylate); Drug: Placebo matching SPD489 (lisdexamfetamine dimesylate)
Sponsor: Shire Pharmaceutical Development
Recruiting - verified March 2010
Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance

Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Biomarkers in the Evaluation of Chronic Lung Disease

Conditions: Pulmonary Hypertension; Pulmonary Arterial Hypertension; Interstitial Lung Disease
Interventions: Other: Blood Gas; Other: Pulmonary Exercise Test; Other: Spirometry; Other: Breath Condensate Collector
Sponsor: North Shore Long Island Jewish Health System
Recruiting - verified March 2010
Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Condition: Psoriasis
Intervention: Drug: CNTO 1959; Placebo
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab (MGA031); Drug: Placebo
Sponsors: MacroGenics; Eli Lilly and Company
Recruiting - verified March 2010
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate plus leuprolide acetate plus prednisone; Drug: leuprolide acetate
Sponsor: Cougar Biotechnology, Inc.
Recruiting - verified March 2010
Study to Evaluate 24 Hour Blood Sugar Control in Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared to Subjects Taking Metformin XR 1500 mg Uptitrated to Metformin XR 2000 mg

Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Metformin XR; Drug: Placebo matching Metformin 500 mg; Drug: Metformin XR; Drug: Placebo matching Saxagliptin 5 mg
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2010
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

Condition: Herpes Zoster in Autologous Hematopoietic Stem Cell Transplantation Recipients
Interventions: Biological: Herpes Zoster Vaccine 1437173A; Biological: Placebo vaccine (saline)
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Virology Follow up Study in Subjects Previously Treated With Telaprevir

Condition: Hepatitis C
Intervention:
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
Non Invasive Biomarkers to Identify Subjects at Risk for Preterm Delivery

Condition: Preterm Birth
Intervention:
Sponsor: Winthrop University Hospital
Recruiting - verified February 2010
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

Conditions: Diabetic Nephropathy; Chronic Kidney Disease
Interventions: Drug: Placebo for Atrasentan 0,2 mg/mL solution; Drug: 0.25 mg Atrasentan QD; Drug: 0.75 mg Atrasentan QD; Drug: 1.75 mg Atrasentan QD
Sponsor: Abbott
Recruiting - verified January 2010
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Condition: Hereditary Angioedema
Interventions: Drug: Icatibant; Drug: Placebo
Sponsors: Jerini AG; Shire Human Genetic Therapies, Inc.
Recruiting - verified November 2009
Study Evaluating Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in ErbB-2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
Study Evaluating 13vPnC in Children With Sickle Cell Disease

Condition: Pneumococcal Conjugate Vaccine
Intervention: Biological: 13vPnC
Sponsor: Wyeth
Recruiting - verified March 2010
Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Conditions: Gastric Cancer; Adenocarcinoma
Interventions: Biological: IMC-1121B; Other: Placebo; Other: Best Supportive Care
Sponsor: ImClone LLC
Recruiting - verified March 2010
Investigation of Neuroserpin as an Autism Candidate Gene

Condition: Autism
Intervention:
Sponsor: State University of New York - Upstate Medical University
Not yet recruiting - verified February 2010
Ablation Versus Anti-Arrhythmic (AA) Drug Therapy for AF - Pivotal Trial

Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone; Drug: 177Lu-J591; Drug: 177Lu-J591; Drug: 177Lu-J591; Drug: 177Lu-J591; Drug: 177Lu-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Melphalan; Drug: Bendamustine; Drug: Bendamustine; Drug: Bendamustine; Drug: Bendamustine
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

Condition: Alzheimer Disease
Interventions: Drug: Dimebon 20 mg po TID; Drug: Placebo po TID
Sponsors: Pfizer; Medivation, Inc.
Recruiting - verified March 2010
Primovist / Eovist in Renally Impaired Patients

Condition: Contrast Media
Intervention: Drug: Eovist (Primovist, BAY86-4873)
Sponsor: Bayer
Recruiting - verified March 2010
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])

Conditions: Hereditary Angioedema; C1 Esterase Inhibitor Deficiency
Intervention: Biological: C1 inhibitor (human)
Sponsor: ViroPharma
Recruiting - verified August 2009
Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Arformoterol; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
A Study of the Safety and Effectiveness of CNTO 328 When Added to Velcade-Melphalan-Prednisone in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: 328 plus VMP (Part 1, Part 2-Arm A); Drug: VMP Alone (Part 2-Arm B)
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma

Condition: Neuroblastoma
Intervention: Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Condition: Colorectal Cancer
Intervention: Drug: olaparib
Sponsors: AstraZeneca; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified February 2010
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

Condition: Acute Coronary Syndrome
Interventions: Drug: Placebo; Drug: GW856553; Drug: GW856553
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Condition: Pseudomonas Infection
Intervention: Drug: Ciprofloxacin (Cipro, BAYQ3939)
Sponsor: Bayer
Recruiting - verified March 2010
Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

Condition: Venous Leg Ulcer
Interventions: Device: Dermagraft(R); Device: Profore
Sponsor: Advanced BioHealing, Inc.
Recruiting - verified February 2010
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic ITP

Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: eltrombopag; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Effect of LY2062430 on the Progression of Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Study of AMG 785 in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing

Condition: Fracture Healing
Interventions: Drug: AMG 785 70mg; Drug: AMG 785 210mg; Drug: AMG 785 140 mg; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
A Prospective, Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)

Conditions: Thrombocytopenia; Idiopathic Thrombocytopenic Purpura
Intervention: Biological: romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
Ventavis® Registry Protocol

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Commercial Ventavis® (iloprost)
Sponsor: Actelion
Recruiting - verified March 2010
The MagnaSafe Registry: Determining the Risks of Magnetic Resonance Imaging (MRI) in the Presence of Pacemakers and Implantable Cardioverter Defibrillators (ICDs)

Conditions: Need for MRI Imaging With Pacemaker or; Implantable Cardioverter Defibrillator Implanted
Intervention:
Sponsor: Scripps Health
Recruiting - verified February 2010
A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver

Condition: Hepatocellular Carcinoma
Interventions: Biological: IMC-A12; Drug: sorafenib
Sponsor: ImClone LLC
Recruiting - verified February 2010
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer

Condition: Chemotherapy Induced Anemia
Interventions: Biological: Biological: ACE-011; Drug: Placebo
Sponsors: Acceleron Pharma, Inc.; Celgene Corporation
Recruiting - verified March 2010
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Surgical Ablation Versus No Surgical Ablation for Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery

Conditions: Atrial Fibrillation; Mitral Valve Insufficiency; Mitral Valve Stenosis
Interventions: Procedure: Mitral valve surgery with ligation/excision of left atrial appendage with ablation; Procedure: Mitral valve surgery with ligation/excision of left atrial appendage
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Institute of Neurological Disorders and Stroke (NINDS); Canadian Institutes of Health Research (CIHR)
Recruiting - verified March 2010
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Imatinib in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effect of LY2062430 on the Progression of Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Intravascular Near Infrared Spectroscopy (NIRS) Bifurcation - Lipid Core Plaque Shift Study

Conditions: Angina Pectoris; Angina, Unstable; Atherosclerosis; Coronary Artery Disease
Intervention: Device: LipiScan Coronary Imaging Catheter
Sponsors: InfraReDx; Columbia University
Recruiting - verified February 2010
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer

Condition: Lung Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster

Conditions: Herpes Zoster; Shingles
Interventions: Drug: valacyclovir; Drug: FV-100; Drug: FV-100; Drug: Valacyclovir placebo; Drug: FV-100 placebo
Sponsor: Inhibitex
Recruiting - verified February 2010
Open Label Study of Sipuleucel-T

Condition: Prostate Cancer
Intervention: Drug: Sipuleucel-T
Sponsor: Dendreon
Recruiting - verified March 2010
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.

Condition: Alzheimer Disease
Intervention: Drug: Placebo
Sponsor: Wyeth
Recruiting - verified March 2010
DNA Analysis of Tumor Tissue Samples From Patients With Recurrent or Metastatic Breast Cancer That Expresses HER2

Condition: Breast Cancer
Interventions: Genetic: comparative genomic hybridization; Genetic: fluorescence in situ hybridization; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: histopathologic examination
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Conditions: HIV Infections; Acquired Immunodeficiency Syndrome
Interventions: Drug: ATV/rtv 400/100mg; Drug: 48 weeks ATV/rtv 300/100mg once daily + ETR 200mg twice daily; Drug: ATV/rtv 300/100mg; Drug: TDF 300mg
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Genetic: microarray analysis; Other: laboratory biomarker analysis
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Other: biologic sample preservation procedure; Procedure: biopsy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

Condition: Glioblastoma Multiforme
Intervention: Drug: Azixa
Sponsor: Myriad Pharmaceuticals
Recruiting - verified February 2010
Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Intervention: Drug: Bendamustine in combination with Rituximab
Sponsor: Cephalon
Recruiting - verified March 2010
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma

Condition: Hodgkin's Lymphoma
Intervention: Drug: ABVD chemotherapy
Sponsor: Weill Medical College of Cornell University
Not yet recruiting - verified March 2010
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)

Condition: Pulmonary Hypertension
Intervention: Drug: UT-15C
Sponsor: United Therapeutics
Recruiting - verified February 2010
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy

Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonneoplastic Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Randomized Withdrawal Study of Desvenlafaxine Succinate Sustained Release in Outpatients With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine succinate sustained release Dose A; Drug: Placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs)

Condition: Coronary Artery Chronic Total Occlusion
Intervention: Device: Recanalization of a coronary chronic total occlusion
Sponsor: BridgePoint Medical
Recruiting - verified March 2010
Self Management in Urinary Catheter Users

Conditions: Urinary Retention; Neurogenic Bladder
Intervention: Behavioral: Self-management of urinary catheter
Sponsors: University of Rochester; Center for Home Care Policy and Research, Visiting Nurse Service of New York
Recruiting - verified February 2010
A Study of Patients With Relapsing Remitting Multiple Sclerosis

Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: LY2127399; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Effect of Vibration Therapy on Bone in Persons With Sub-acute Spinal Cord Injury

Condition: Spinal Cord Injuries
Intervention: Device: Mechanical Stimulation with the Vibration Plate
Sponsors: Department of Veterans Affairs; Kessler Foundation
Recruiting - verified February 2010
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension
Intervention: Drug: Ambrisentan or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: ixabepilone
Sponsor: Eisai Inc.
Recruiting - verified March 2010
Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease

Condition: Alzheimer Disease
Interventions: Drug: RO5313534; Drug: RO5313534; Drug: RO5313534; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Condition: Epidermolysis Bullosa
Intervention: Drug: Reduced Intensity Transplant conditioning
Sponsor: Columbia University
Recruiting - verified March 2010
Functional and Physiological Responses to Lokomat Therapy (Pilot Study)

Conditions: Spinal Cord Injuries; Multiple Sclerosis; Stroke
Intervention:
Sponsor: Department of Veterans Affairs
Recruiting - verified February 2010
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

Condition: Depression
Interventions: Drug: orvepitant; Other: placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Condition: Euvolemic Hyponatremia
Interventions: Drug: Lixivaptan; Drug: Placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified March 2010
A Study of Tanezumab in Adults With Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 10 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 5 mg IV; Drug: Placebo for naproxen; Biological: Placebo for tanezumab; Drug: Naproxen; Biological: Placebo for tanezumab; Drug: Placebo for naproxen
Sponsor: Pfizer
Recruiting - verified March 2010
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

Condition: Myocardial Infarction
Interventions: Drug: Prochymal®; Drug: Placebo
Sponsor: Osiris Therapeutics
Recruiting - verified March 2010
A Trial of CM-AT in Children With Autism

Condition: Autism
Interventions: Drug: CM-AT; Drug: Placebo
Sponsor: Curemark
Recruiting - verified March 2010
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

Condition: Depression
Interventions: Other: Placebo; Drug: orvepitant
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Conditions: Neuroblastoma; Bone Marrow, Sympathetic Nervous System
Intervention: Other: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone in Post Menopausal Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Bosutinib; Drug: Letrozole
Sponsor: Wyeth
Recruiting - verified March 2010
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

Condition: Herpes Labialis
Intervention: Drug: Famciclovir
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Laparoscopic Radiofrequency Ablation of Symptomatic Uterine Fibroids

Conditions: Uterine Fibroids; Uterine Myomas
Intervention: Device: Halt System
Sponsor: Halt Medical, Inc
Recruiting - verified March 2010
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Noninvasive Test for Fetal RHD Genotype

Condition: Rhesus D Genotype
Intervention:
Sponsors: Sequenom, Inc.; NAFTNet
Recruiting - verified March 2010
A Study to Test IMC-A12 With and Without Other Standard Chemotherapies in Patients With Lung Cancer Who Have Not Received Chemotherapy Before

Condition: Non-small Cell Lung Cancer
Interventions: Biological: Cetuximab; Drug: Gemcitabine; Drug: Carboplatin; Biological: IMC-A12; Drug: Cisplatin
Sponsor: ImClone LLC
Recruiting - verified February 2010
Thiazolidinedione Intervention With Vitamin D Evaluation

Conditions: Cardiovascular Disease; Type 2 Diabetes Mellitus
Interventions: Drug: pioglitazone; Drug: placebo; Dietary Supplement: vitamin D; Dietary Supplement: placebo; Drug: rosiglitazone
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
PDE5 Inihibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsor: Bayer
Recruiting - verified March 2010
Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer
Intervention: Behavioral: online platform "STAR" (Symptom Tracking and Reporting for Patients)
Sponsors: Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified March 2010
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: imatinib mesylate
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

Condition: Bipolar I, Depression
Intervention: Drug: lurasidone
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

Conditions: Bipolar; Depression
Interventions: Drug: lurasidone; Drug: lurasidone; Drug: Placebo
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Condition: Epilepsy With Simple or Complex Partial Onset Seizures
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsor: Sepracor, Inc.
Recruiting - verified March 2010
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: RO5024048; Drug: Pegasys; Drug: Pegasys; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633AM1)

Conditions: Coronary Artery Bypass; Myocardial Infarction; Ventricular Dysfunction, Left; Stroke; Cardiopulmonary Bypass
Interventions: Drug: Acadesine; Drug: Normal Saline
Sponsor: Schering-Plough
Recruiting - verified March 2010
Donor Stem Cell Transplant in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma After First Complete Remission

Condition: Lymphoma
Interventions: Biological: graft-versus-tumor induction therapy; Biological: rituximab; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methotrexate; Drug: tacrolimus; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: quality-of-life assessment
Sponsors: Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified February 2010
A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma

Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane; Drug: Placebo, Exemestane
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Carcinoma
Interventions: Drug: Pazopanib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Iron & Vitamin C Study

Condition: Spinal Cord Injury
Intervention:
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

Condition: Bipolar Depression
Interventions: Drug: lurasidone + (lithium or divalproex); Drug: Placebo + (lithium or divalproex)
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Chemotherapy or Observation in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate; Procedure: standard follow-up care
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Condition: Behcet Syndrome
Interventions: Drug: Apremilast (CC-10004); Drug: Placebo
Sponsor: Celgene Corporation
Recruiting - verified March 2010
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

Conditions: Actinic Keratoses; Skin Neoplasms
Interventions: Drug: Aminolevulinic Acid; Other: Vehicle
Sponsor: DUSA Pharmaceuticals, Inc.
Recruiting - verified March 2010
Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (Study P05522)

Condition: Primary Hypercholesterolemia
Interventions: Drug: ezetimibe; Drug: Placebo
Sponsors: Schering-Plough; Merck
Recruiting - verified March 2010
Tanezumab in Osteoarthritis of the Hip or Knee (2)

Condition: Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Pain Therapy in HIV Neuropathy

Conditions: HIV Infections; Peripheral Neuropathy
Interventions: Drug: Duloxetine; Drug: Duloxetine placebo; Drug: Methadone; Drug: Methadone placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Concentration and Activity of Lapatinib in Vestibular Schwannomas

Conditions: Vestibular Schwannoma; NF2; Neurofibromatosis 2; Acoustic Neuroma; Auditory Tumor
Intervention: Drug: lapatinib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Children's Tumor Foundation; GlaxoSmithKline; New York University; Ohio State University; House Ear Institute
Recruiting - verified February 2010
Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy

Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: 177Lu-J591; Drug: Ketoconazole; Drug: Hydrocortisone; Drug: 111In-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Subjects With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Alogliptin and metformin; Drug: Alogliptin and metformin; Drug: Glipizide and metformin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for the Treatment of Rheumatoid Arthritis in Patients on Other Background Arthritis Medications

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Growth Factor Signature (GFS) Pilot Study

Conditions: Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia; Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia
Intervention: Other: Comparator: Biomarker evaluation
Sponsor: Merck
Recruiting - verified March 2010
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Safety & Efficacy Study in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

Conditions: Insomnia; Attention Deficit Hyperactivity Disorder
Interventions: Drug: eszopiclone; Drug: eszopiclone; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

Conditions: Herpes Zoster; HIV Infections
Interventions: Biological: Zoster Vaccine Live; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical Trials Group; Merck
Recruiting - verified May 2009
A Pharmacokinetics (Blood Levels), Pharmacodynamics (How the Drug Acts on the Body) and Safety Study Dosing of Rabeprazole in New Borns With Gastroesophageal Reflux Disease (GERD).

Condition: Gastroesophageal Reflux
Intervention: Drug: Rabeprazole sodium
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified February 2010
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With TMC114r (Ritonavir), and TMC125 (Etravirine) in HIV-1 Infected Pregnant Women

Conditions: HIV; HIV Infections; Pregnancy
Interventions: Drug: TMC114 (darunavir); Drug: TMC125 (etravirine); Drug: TMC114r (ritonavir)
Sponsors: Tibotec, Inc; Tibotec Therapeutics, a Division of Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Conditions: HIV Infections; Treatment Naive
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Prospective Multicenter Post Approval Study of the LPS-Flex Mobile Bearing Knee

Conditions: Osteoarthritis; Traumatic Arthritis; Avascular Necrosis of the Femoral Condyle; Moderate Varus; Valgus; Flexion Deformities
Intervention: Device: NexGen LPS-Flex Mobile Bearing Knee
Sponsor: Zimmer, Inc.
Recruiting - verified March 2010
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Conditions: Bladder Cancer; Urinary Bladder
Intervention: Drug: Gemcitabine, Cisplatin, and Sunitinib
Sponsors: Memorial Sloan-Kettering Cancer Center; Pfizer
Recruiting - verified March 2010
An Observational Study of Fungal Biomarkers

Condition: Aspergillosis
Intervention: Other: No Intervention
Sponsor: Merck
Recruiting - verified March 2010
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

Conditions: Impetigo; Secondarily-infected Traumatic Lesions
Interventions: Drug: Linezolid; Drug: Retpamulin Ointment, 1%
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Quality of Life in Patients With Statin-Associated Myopathy

Condition: Statin-Associated Myopathy
Interventions: Drug: Statins; Drug: Lactose placebo pills
Sponsors: Rockefeller University; Cornell University; Adelphi University
Recruiting - verified March 2010
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: duloxetine; Drug: Placebo; Drug: fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Evaluating Post-test HIV Counseling Videos for Teens

Conditions: HIV; HIV Infections
Intervention: Behavioral: Video
Sponsors: North Bronx Healthcare Network; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2010
A Comparison of Two Freezing Techniques

Condition: Infertility
Intervention: Procedure: oocyte freezing
Sponsors: North Shore Long Island Jewish Health System; EMD Serono
Recruiting - verified March 2010
Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

Condition: Bipolar Depression
Interventions: Drug: cariprazine; Drug: cariprazine; Drug: placebo
Sponsors: Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2010
Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis

Conditions: Gastroparesis; Diabetic Gastroparesis; Diabetes; Diabetes Mellitus; Delayed Gastric Emptying
Interventions: Drug: metoclopramide; Drug: Placebo
Sponsor: Evoke Pharma
Recruiting - verified March 2010
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Conditions: B-Cell Lymphoma; B-Cell Leukemia
Intervention: Drug: PCI-32765
Sponsor: Pharmacyclics
Recruiting - verified July 2009
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

Condition: Colorectal Cancer (CRC)
Interventions: Drug: Irinotecan; Drug: 5-Fluorouracil (bolus); Drug: 5-Fluorouracil (infusional); Drug: Leucovorin calcium; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab Placebo (saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Family Weight Management Study

Conditions: Obesity; Diabetes
Intervention: Behavioral: lifestyle intervention
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2010
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Open-Label Study of Oral Treprostinil in Digital Ulcers

Condition: Systemic Sclerosis
Intervention: Drug: treprostinil diethanolamine
Sponsor: United Therapeutics
Not yet recruiting - verified February 2009
A Trial of Patients With Metastatic Adenocarcinoma of the Pancreas

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified December 2009
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis

Condition: Psoriasis
Interventions: Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 subcutaneous injection
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse

Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
Efficacy and Safety of TAK-491 Combined With Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Chlorthalidone; Drug: Chlorthalidone; Drug: TAK-491; Drug: TAK-491; Drug: TAK-491
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Efficacy and Safety of Azilsartan Plus Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer

Conditions: Cancer; Carcinoma; Castrate-Resistant Prostate Cancer; Prostate Cancer; Tumors
Intervention: Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression

Condition: Bipolar Depression
Interventions: Drug: Olanzapine Fluoxetine Combination; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY451395; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Phase III Acute Coronary Syndrome

Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of of MORAb-004 in Subjects With Solid Tumors

Condition: Solid Tumor
Intervention: Drug: MORAb-004 (monoclonal antibody to TEM1)
Sponsor: Morphotek
Recruiting - verified March 2010
Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

Condition: Acute Decompensated Heart Failure
Intervention: Drug: CD-NP
Sponsor: Nile Therapeutics
Recruiting - verified March 2010
An Observational Study of Cholesterol in Coronary Arteries

Conditions: Myocardial Infarction; Angina; Coronary Artery Disease; Myocardial Ischemia
Intervention: Device: Intravascular Near Infrared Spectroscopy
Sponsor: InfraReDx
Recruiting - verified February 2010
An Alternative Dosing Schedule of Varenicline for Smoking Cessation

Condition: Smoking Cessation
Interventions: Drug: varenicline; Drug: placebo
Sponsors: Roswell Park Cancer Institute; Pfizer
Recruiting - verified March 2010
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Cetuximab; Drug: Paclitaxel; Drug: Carboplatin; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: Accelerated Community Oncology Research Network; ImClone LLC; Advanced Clinical Trial Solutions, LLC
Recruiting - verified February 2010
Tanezumab In Osteoarthritis Of The Knee (2)

Conditions: Arthritis; Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors

Conditions: Brain Cancer; Gliomas
Intervention: Radiation: [18F]FACBC PET and [18F]FLT PET imaging
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials

Condition: Solid Tumors
Intervention: Drug: AG-013736
Sponsor: Pfizer
Recruiting - verified March 2010
Trial of Mifepristone in Combat Veterans With Posttraumatic Stress Disorder

Condition: Posttraumatic Stress Disorder
Interventions: Drug: mifepristone; Drug: placebo
Sponsor: James J. Peters Veterans Affairs Medical Center
Recruiting - verified February 2010
Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

Condition: Plaque Psoriasis
Interventions: Drug: Acitretin (also called U0279); Drug: Placebo; Biological: Etanercept
Sponsor: Stiefel, a GSK Company
Recruiting - verified February 2010
Safety of Urate Elevation in Parkinson's Disease

Condition: Parkinson Disease
Interventions: Drug: Placebo; Drug: inosine; Drug: inosine
Sponsors: The Parkinson Study Group; Massachusetts General Hospital; Harvard School of Public Health; University of Rochester; Michael J. Fox Foundation for Parkinson's Research
Recruiting - verified March 2010
Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Condition: Liver Cancer
Interventions: Drug: Brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Comparison Study of Daily Ultrafiltration and Twice-weekly Hemodialysis

Condition: End-Stage Renal Disease
Intervention: Procedure: Ultrafiltration
Sponsors: Renal Research Institute; Vizio Medical Devices
Recruiting - verified March 2010
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Condition: Human Immunodeficiency Virus-1
Interventions: Drug: maraviroc; Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C

Condition: Chronic Hepatitis C
Intervention: Procedure: Comparator: Fine needle aspiration biopsy
Sponsor: Merck
Recruiting - verified March 2010
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1; Drug: UK-453,061 Dose 2; Drug: Etravirine
Sponsor: Pfizer
Recruiting - verified February 2010
A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

Condition: HIV-1
Interventions: Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed
Sponsor: Pfizer
Recruiting - verified February 2010
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

Condition: Multiple Sclerosis
Intervention: Other: Single-Use Autoinjector with a Pre-Filled Liquid Avonex Syringe
Sponsor: Biogen Idec
Recruiting - verified February 2010
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease

Condition: Alzheimer´s Disease
Interventions: Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%); Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%); Other: Placebo solution
Sponsors: Baxter Healthcare Corporation; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified March 2010
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

Condition: HIV Infections
Interventions: Biological: Vaccine; Biological: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158

Condition: Ischemia
Interventions: Other: BMS747158; Other: BMS747158
Sponsor: Lantheus Medical Imaging
Recruiting - verified March 2010
Post-Market Study of the 3DKnee™ System

Conditions: Degenerative Joint Disease; Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis
Intervention: Device: 3DKnee™ System
Sponsor: Encore Medical, L.P.
Recruiting - verified March 2010
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; Baylor College of Medicine
Recruiting - verified March 2010
A Study of Ridaforolimus in Non-Small Cell Lung Cancer Patients With KRAS Mutations

Condition: Non-small Cell Lung Cancer
Interventions: Drug: deforolimus; Drug: Comparator: Blinded Ridaforolimus; Drug: Comparator: Blinded Placebo
Sponsors: Merck; Ariad Pharmaceuticals
Recruiting - verified March 2010
PF-00299804 As A Single Oral Agent In Untreated Adenocarcinoma Of The Lung In Non-Smokers Or Former Light Smokers

Condition: Carcinoma, Non-small Cell
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Comparative Study of Three NNRTI-Sparing HAART Regimens

Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Raltegravir; Drug: Darunavir; Drug: Ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb; Gilead Sciences; Merck; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Recruiting - verified June 2009
Phase 2 Safety & Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 vs FOLFIRI in KRAS-mutant Metastatic Colorectal Carcinoma

Condition: Metastatic Colorectal Cancer
Interventions: Biological: AMG 479; Other: Placebo; Other: FOLFIRI; Biological: AMG 655
Sponsor: Amgen
Recruiting - verified March 2010
Extension Study Of Tanezumab In Osteoarthritis

Condition: Osteoarthritis
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab
Sponsor: Pfizer
Recruiting - verified March 2010
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

Conditions: Osteoarthritis; Arthritis
Interventions: Drug: NSAID; Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Drug: NSAID; Biological: tanezumab; Drug: NSAID
Sponsor: Pfizer
Recruiting - verified March 2010
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome.

Conditions: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina
Intervention: Drug: Rivaroxaban; Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Bayer
Recruiting - verified February 2010
Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone Immediate Release (IR) for Treatment of Acute Post-op Pain Following Elective Arthroscopic Shoulder Surgery

Condition: Postoperative Pain
Interventions: Drug: Oxycodone IR; Drug: Tapentadol IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Recruiting - verified February 2010
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

Condition: Waldenstrom's Macroglobulinemia
Intervention: Biological: Ofatumumab
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: Folic Acid; Drug: BIBF1120 placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsor: Bayer
Recruiting - verified March 2010
Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis

Conditions: Lupus; Nephritis; Systemic Lupus Erythematosus
Intervention: Drug: AMG 811
Sponsor: Amgen
Recruiting - verified February 2010
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

Condition: Advanced or Metastatic ErbB2-overexpressing Breast Cancer
Intervention: Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation

Conditions: Mitral Valve Insufficiency; Coronary Artery Disease
Interventions: Procedure: Mitral Valve Repair with Annuloplasty; Procedure: Mitral Valve Replacement
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010
Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation

Conditions: Mitral Valve Insufficiency; Coronary Artery Disease
Interventions: Procedure: Mitral Valve Repair; Procedure: CABG
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Conditions: Breast Cancer; Breast Neoplasms; Breast Tumors; Cancer; Locally Recurrent and Metastatic Breast Cancer; Metastases; Metastatic Cancer; Oncology; Solid Tumors; Tumors
Interventions: Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab; Drug: AMG 386 3 mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 3 mg/kg, Capecitabine and Lapatinib
Sponsor: Amgen
Recruiting - verified March 2010
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

Condition: Asthma
Interventions: Drug: Levalbuterol; Drug: Levalbuterol UDV TID; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

Condition: Idiopathic Restless Legs Syndrome
Interventions: Drug: placebo and pregabalin; Drug: pramipexol; Drug: pramipexol; Drug: Pregabalin; Drug: pramipexol; Drug: pramipexol
Sponsor: Pfizer
Recruiting - verified March 2010
Study of Ataluren (PTC124™) in Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124); Drug: Placebo
Sponsors: PTC Therapeutics; Genzyme; Cystic Fibrosis Foundation
Recruiting - verified March 2010
Study of NNZ-2566 in Patients With Traumatic Brain Injury

Condition: Brain Injuries
Intervention: Drug: NNZ-2566
Sponsor: Neuren Pharmaceuticals Limited
Not yet recruiting - verified March 2010
Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients With Chronic Plaque Psoriasis (Ps)

Condition: Chronic Plaque Psoriasis
Intervention: Biological: HUMIRA® (adalimumab)
Sponsor: Abbott
Recruiting - verified January 2010
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Conditions: Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease; CV Risk
Interventions: Drug: Darapladib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Condition: Melanoma
Interventions: Drug: AntiCD137; Drug: AntiCD137; Drug: AntiCD137; Drug: AntiCD137; Drug: AntiCD137; Drug: Ipilimumab
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified November 2009
Rollover Protocol for Prior SU011248 Protocols

Condition: Solid Tumors
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299, GSK Biological's HPV vaccine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: RO4998452; Drug: RO4998452; Drug: RO4998452; Drug: RO4998452; Drug: RO4998452; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Open-label Study Providing Monotherapy (Sitaxsentan) and Combination Therapy (Sitaxsentan+Sildenafil) to Subjects With PAH to Assess Long-term Safety

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Not yet recruiting - verified March 2010
SR-PAAS - Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: PAH; Pulmonary Arterial Hypertension; Pulmonary Hypertension; Sitaxsentan; ETRA
Interventions: Drug: Sitaxsentan; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; ETRA; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Recruiting - verified March 2010
Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: pemetrexed disodium; Genetic: gene expression analysis; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Procedure: quality-of-life assessment
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Other: active surveillance
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sitagliptin Cardiovascular Outcome Study

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Comparator: Placebo
Sponsors: Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified March 2010
Polycystic Kidney Disease Data Repository

Condition: Polycystic Kidney Disease
Intervention:
Sponsors: Rockefeller University; The Rogosin Institute; Memorial Sloan-Kettering Cancer Center; New York Presbyterian Hospital; Temple University
Recruiting - verified March 2010
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Moderate to Severe Plaque Psoriasis With Scalp Involvement

Condition: Psoriasis
Interventions: Drug: etanercept / placebo; Drug: placebo / etanercept
Sponsor: Amgen
Recruiting - verified February 2010
Bevacizumab and Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

Condition: Chronic Schizophrenia
Interventions: Drug: Lurasidone HCl; Drug: quetiapine XR
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

Condition: Schizophrenia
Interventions: Drug: Lurasidone HCl; Drug: Lurasidone HCl; Drug: quetiapine XR; Drug: Placebo
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
PEAK: A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS Tumors

Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsor: Amgen
Recruiting - verified March 2010
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Conditions: Cancer; Solid Tumors
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Phase II Study of TKI258 in Advanced Urothelial Carcinoma

Condition: Urothelial Cancer
Intervention: Drug: TKI258
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Liothyronine (T3) for Bipolar Depression

Conditions: Depression; Bipolar Disorder
Interventions: Drug: Liothyronine (T3); Drug: placebo
Sponsors: North Shore Long Island Jewish Health System; National Alliance for Research on Schizophrenia and Depression
Recruiting - verified March 2010
An Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233AM1)

Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Conditions: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
Interventions: Drug: maraviroc; Drug: etravirine
Sponsor: Pfizer
Recruiting - verified March 2010
Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Condition: Advanced Breast Cancer
Interventions: Drug: Bosutinib; Drug: Exemestane
Sponsor: Wyeth
Recruiting - verified February 2010
PKUDOS: PKU Demographic, Outcomes, and Safety Registry

Conditions: Phenylketonuria; Hyperphenylalaninaemia
Intervention: Drug: Sapropterin Dihydrochloride
Sponsor: BioMarin Pharmaceutical
Recruiting - verified January 2010
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.

Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

Conditions: Lupus Nephritis; Lupus Erythematosus, Systemic
Interventions: Drug: Abatacept; Drug: cyclophosphamide; Drug: azathioprine; Drug: prednisone; Drug: abatacept placebo; Drug: azathioprine placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified February 2010
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; VasCore at Massachusetts General Hospital
Recruiting - verified February 2010
Bicalutamide and Ridaforolimus in Men With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: ridaforolimus (MK8669); Drug: Comparator: Placebo; Drug: open-label ridaforolimus (MK8669)
Sponsors: Merck; Ariad Pharmaceuticals
Recruiting - verified March 2010
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

Conditions: Systemic Sclerosis; Scleroderma
Interventions: Drug: treprostinil diethanolamine; Drug: placebo
Sponsor: United Therapeutics
Recruiting - verified February 2010
Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy

Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
NINDS CRC Chronic Migraine Treatment Trial

Condition: Chronic Migraine
Interventions: Drug: propranolol LA; Drug: topiramate; Drug: placebo
Sponsors: The EMMES Corporation; National Institute of Neurological Disorders and Stroke (NINDS); Ortho-McNeil Janssen Scientific Affairs, LLC; CRC Operations Center
Recruiting - verified March 2010
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care

Condition: Asthma
Interventions: Drug: tiotropium 5mcg/day; Drug: tiotropium 5mcg/day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohns Disease Who Have Been Previously Treated With Anti-TNF Therapy

Condition: Crohn's Disease
Intervention: Drug: Ustekinumab; CNTO1275
Sponsor: Centocor, Inc.
Recruiting - verified March 2010
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
An Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234AM2)

Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 1.5 Amb a 1-U; Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Paclitaxel and Trastuzumab and/or Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
(ARTEMIS-IPF)Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

Condition: Back Pain
Interventions: Drug: placebo; Drug: tapentadol IR; Drug: oxycodone IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Not yet recruiting - verified February 2010
Study of Focal Cryoablation in Low-Risk Prostate Cancer

Condition: Prostate Cancer
Intervention: Procedure: focal cryotherapy
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU

Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsor: USHIFU, LLC
Recruiting - verified March 2010
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Condition: Systemic Lupus Erythematosus
Interventions: Other: Sugar Pill; Drug: N-acetylcysteine; Drug: N-acetylcysteine; Drug: N-acetylcysteine; Drug: N-acetylcysteine
Sponsor: State University of New York - Upstate Medical University
Recruiting - verified February 2010
Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma

Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU

Condition: Intensive Care Unit
Intervention: Drug: ceftobiprole
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Viral Shedding of MEDI-559 in Healthy 1 to <24 Month-Old Children

Condition: Healthy
Interventions: Biological: MEDI-559; Other: Placebo; Biological: MEDI-559
Sponsor: MedImmune LLC
Recruiting - verified March 2010
Hydroxychloroquine in Untreated B-CLL Patients

Condition: B-cell Chronic Lymphocytic Leukemia
Intervention: Drug: Hydroxychloroquine
Sponsor: North Shore Long Island Jewish Health System
Recruiting - verified March 2010
Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Biological: tositumomab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Radiation: iodine I 131 tositumomab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

Condition: Glioblastoma Multiforme
Interventions: Drug: CT-322; Drug: Temozolomide; Procedure: Radiation Therapy
Sponsor: Adnexus, A Bristol-Myers Squibb R&D Company
Recruiting - verified March 2010
Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected Antiretroviral Treatment Experienced Children and Adolescents

Condition: HIV Infections
Intervention: Drug: Vicriviroc
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2009
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

Condition: Scleroderma
Intervention: Drug: dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Condition: Optic Neuropathy, Ischemic
Intervention:
Sponsor: Pfizer
Recruiting - verified March 2010
Feasibility of "At-home" Titration of Solifenacin

Condition: Overactive Bladder
Intervention: Drug: Solifenicin (Vesicare)
Sponsor: New York University School of Medicine
Recruiting - verified March 2010
Duloxetine for Multiple Sclerosis Pain

Condition: Multiple Sclerosis
Interventions: Drug: Duloxetine HCI; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: rhGAD65; Drug: rhGAD65; Drug: Placebo
Sponsor: Diamyd Therapeutics AB
Recruiting - verified March 2010
Safety and Efficacy of Positron Emission Tomography Imaging With BAY 94-9172 (ZK 6013443)

Conditions: Alzheimer Disease; Amyloid Beta-Protein
Intervention: Drug: BAY94-9172 (ZK 6013443)
Sponsor: Bayer
Recruiting - verified March 2010
Study to Promote Weight Loss in Primary Care Practices

Condition: Obesity
Interventions: Behavioral: Individual telephone intervention; Behavioral: Group telephone intervention
Sponsors: State University of New York - Upstate Medical University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Condition: Neoplasms
Intervention: Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
A Placebo-Controlled Study of AZD0530 in Patients With Recurrent Osteosarcoma Localized to the Lung

Condition: Osteosarcoma
Interventions: Drug: AZD0530; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; AstraZeneca
Recruiting - verified February 2010
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN®; Drug: Carboplatin; Drug: Paclitaxel
Sponsor: Oncolytics Biotech
Recruiting - verified March 2010
Lumbar Spinal Fusion System

Condition: Degenerative Disc Disease
Intervention:
Sponsor: Biomet, Inc.
Recruiting - verified March 2010
MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions

Condition: Myelodysplastic Syndrome (MDS)
Intervention: Other: T2* Cardiac and Liver MRI
Sponsors: Weill Medical College of Cornell University; Novartis Pharmaceuticals
Recruiting - verified March 2010
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Condition: Ovarian Cancer
Intervention: Biological: bevacizumab
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Tanezumab in Osteoarthritis Of The Hip

Conditions: Arthritis; Osteoarthritis; Osteoarthritis, Hip
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Biological: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Condition: Sarcoma
Interventions: Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Drug: zoledronic acid; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Condition: Advanced Breast Cancer
Interventions: Drug: Dasatinib + Fulvestrant; Drug: Fulvestrant
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: Temozolomide; Drug: Temozolomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Schering-Plough
Recruiting - verified February 2010
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: ASA404 in combination with docetaxel; Drug: Placebo in combination with docetaxel
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Renal Insufficiency After the Administration of Magnevist

Conditions: Fibrosis; Kidney Failure; Renal Insufficiency
Intervention: Procedure: Lab sample drawn for serum chemistry at baseline visit
Sponsor: Bayer
Recruiting - verified March 2010
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010

Find Paid Clinical Trials in New York, New York - Clinical Trials

Find Paid Clinical Trials in New York, New York

Paid Clinical Trials and Focus Groups by Location